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1  | INTRODUC TION
Bone metastases are a frequent occurrence in cancer patients, de‐
veloping in one third of cases and resulting in pain associated with 
considerable morbidity (Van Oorschot, Rades, Schulze, Beckmann, 
& Feyer, 2011). Traditional management of symptomatic bone lesion 
encompass surgery in selected patients, pharmacological interven‐
tions (pain medication, bisphosphonates) and conventional fraction‐
ated radiotherapy (CRT) to painful sites (Chow et al., 2012).
In recent years, use of stereotactic body radiotherapy (SBRT), a 
highly focused ablative radiotherapy technique, has been reported 
by multiple institutions for the treatment of bone metastases, show‐
ing promising results in terms of local control, pain relief, safety and 
cost‐effectiveness (Bhattacharya & Hoskin, 2015) though no direct 
comparison is available with CRT (De Bari et al., 2016). This is of 
primary interest in patients with limited disease burden, consisting 
of	≤3	concurrent	metastases,	who	experience	longer	lifespan	com‐
pared	to	patients	with	extensively	disseminated	disease	(Jacobson,	
Shapiro, Abbeele, & Kaplan, 2001). In this subset of metastatic pa‐
tients, defined as “oligometastatic,” the achievement of long‐last‐
ing analgesia and local control is particularly desirable. In a recent 
multi‐institutional retrospective cohort, long‐term disease control 
and survival were obtained following ablative radiotherapy for oligo‐
metastatic patients: most notably, bone metastatic involvement was 
not correlated with impaired efficacy, while a dose correlation with 
local control was seen in this subset of patients (Hong et al., 2018).
However,	 cancer	 pain	 is	 a	 complex	 clinical	 entity:	Due	 to	 het‐
erogeneity in the population of patients affected by painful bone 
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Abstract
The aim of our study was to assess the incidence of pain flare and the effectiveness 
of stereotactic body radiotherapy (SBRT) in pain management of patients with bone 
oligometastases. We evaluated 48 patients accounting for 54 treatments. The 
Edmonton Classification System for Cancer Pain (ECS‐CP) was applied to identify 
indicators	of	treatment‐resistant	pain,	in	patients	with	active	pain	(NRS	≥	2)	at	base‐
line. Statistical analysis was performed to identify predictors of pain flare and pain 
control.	Pain	 flare	occurred	 in	38%	of	 treated	patients	 (n = 18/48): No correlation 
was found between pain flare and patient‐ or treatment‐related variables. In the sub‐
set of patients with active pain at baseline (n	=	23),	pain	control	was	obtained	in	62%	
of patients at 1 year; median time to pain progression after SBRT was 29 months 
(CI95%	6–52	months).	 Presence	of	≥2ECS‐CP	 features	was	 correlated	with	 earlier	
pain	progression	(4	vs.	30	months,	p	=	0.012).	Pain	flare	occurred	in	38%	of	cases	ir‐
respectively of steroid premedication and dose regimen. In patient with baseline ac‐
tive	pain,	durable	pain	control	was	obtained.	Presence	of	≥2	complexity	indicators	at	
the ECS‐CP assessment was correlated with impaired pain control and may deserve 
future investigation in prospective studies.
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metastases, it is of primary concern to identify patients who can 
benefit most from this approach and to assess its role in pain man‐
agement. Multiple tools are available to further characterise chronic 
pain in cancer patients, in order to provide elements for clinical de‐
cision, but their use in the radiotherapy setting is limited. Among 
them, the Edmonton Classification System for Cancer Pain (ECS‐CP) 
proved effective in predicting resistance to pain treatment accord‐
ing	to	the	presence	of	five	complexity	features	(neuroceptive	com‐
ponent, incident pain, psychological distress, addictive behaviour 
and cognitive impairment; Fainsinger et al., 2005).
SBRT	has	common	radiotherapy‐related	toxicities:	 In	particular	
pain flare, a temporary increase in pain at the treated site (De Bari 
et al., 2016). Pain flare, despite its transient nature, is perceived as 
a debilitating and worrisome event by the majority of patients, with 
important drawbacks on daily activities and insufficient relief from 
increased pain medication (Hird et al., 2009). So, SBRT is a double‐
edged sword: On the one hand, it is used as a long‐lasting pain killer 
but on the other hand it can cause a pain flare. The aims of the study 
were to evaluate the variations in pain following stereotactic radio‐
therapy	 to	 bone	metastases	 (spinal	 and	 extraspinal).	We	 assessed	
the incidence of pain flare following the first treatment fraction and 
the pain control after the treatment and their respective predictive 
factors.
2  | MATERIAL S AND METHODS
2.1 | Patient selection, procedures and follow‐up
A	retrospective	 review	of	oligometastatic	 (≤3	concurrent	metas‐
tases) patients treated at our Institution between May 2005 and 
September 2016 with stereotactic radiotherapy for at least one 
bone metastasis was performed after obtainment of informed 
consent. Pain at the treated site was evaluated at baseline and 
during clinical follow‐up after treatment using the Numeric Rating 
Scale (NRS) and Visual Analog Scale (VAS; Paice & Cohen, 1997). 
In	patient	with	NRS	≥	2	at	baseline,	active	pain	was	further	classi‐
fied using the ECS‐CP 5 items tool. Pain medications were classi‐
fied according to the WHO three‐step ladder, consisting of step 1 
drugs (paracetamol, NSAIDs), step 2 drugs (mild opioids: codeine, 
dihydrocodeine	or	tramadol)	and	step	3	drugs	(strong	opioids:	mor‐
phine,	fentanyl,	buprenorphine,	oxymorphone,	oxycodone	or	hy‐
dromorphone; WHO’s Pain Ladder, 1986). Stereotactic treatment 
was delivered using the CyberKnife radiotherapy system (Accuray 
Inc, Sunnyvale, CA). Volumes delineation and dose calculation 
were performed using the Multiplan Treatment Planning System. 
The gross tumour volume (GTV) was identified as the visible lesion 
on fused diagnostic imaging (MRI, contrast‐enhanced CT or PET‐
CT). Planning target volume (PTV) included the GTV or, if present, 
the	CTV	plus	a	2–5	mm	margin.	Before	2012,	 the	PTV	for	spinal	
metastases	equalled	to	the	GTV	plus	a	2–3	mm	margin,	and	after	
2012, volumes were delineated according to the ISRC consensus 
recommendations	(Cox	et	al.,	2012).	The	total	dose	was	prescribed	
to	 the	outer	 line	of	 the	PTV	 to	 the	80%–90%	 isodose	 line	using	
different single or multiple fraction schedules. Dose constraints 
for OARs were applied according to the American Association of 
Physicists in Medicine (AAPM) recommendations (Benedict et al., 
2010). To take into account different dose fractionation, all the 
dosimetric variables were recalculated as equivalent dose in 2 Gy 
(EQD2) with an α/β	=	10	and	3	for	early	and	late	reacting	tissues	re‐
spectively. For every treatment, patient‐related data (age, gender, 
primary tumour, ECOG performance status, prior chemotherapy, 
number	of	metastases,	spinal/extraspinal	localisation,	lytic/solid/
mixed	radiological	aspect,	pain	at	baseline,	use	and	dosage	of	an‐
algesics, use and dosage of steroids) and radiotherapy‐related data 
(single/multiple fraction dose schedule, total dose delivered, GTV 
and	PTV	volume,	minimum	dose	to	the	PTV,	maximum	dose	to	the	
PTV, mean dose to the PTV) were collected. Likewise, opioids and 
steroid dosage (in milligrams) were reconverted in oral‐morphine 
equivalent	 (OME)	and	dexamethasone	equivalent	 (DXE)	 to	allow	
for comparison. According to institutional guidelines, follow‐up 
visits	were	scheduled	at	1,	3	and	6	months	and	subsequently	once	
a year. All procedures in our study were performed in accordance 
with the ethical standards of the National Research Committee 
and with the 1964 Helsinki declaration and its later amendments 
or comparable ethical standards.
2.2 | Definition of endpoints
Pain flare was defined as a temporary (resolving within subsequent 
clinical	 evaluation)	 ≥2–points	 increase	 in	 the	NRS	pain	 scale	 com‐
pared	to	baseline	levels	with	no	decrease	in	analgesic	intake	or	+25%	
increase in analgesic intake with no decrease in pain score (Chow, 
Ling,	Davis,	Panzarella,	&	Danjoux,	2005).
Pain progression (PP) was defined as durable increase of pain 
score	 of	 ≥2	 points	 above	baseline	 at	 the	 treated	metastatic	 site	
with	stable	analgesic	use	or	increase	≥25%	in	daily	oral‐morphine	
equivalent compared with pretreatment intake, with stable pain 
score (Chow et al., 2005). Pain control (PC) was defined as time 
from treatment start date to PP. Overall survival (OS) was mea‐
sured from start of the radiation therapy until death from any 
cause.
2.3 | Statistical analysis
Descriptive statistics were used to report patient‐ and treatment‐re‐
lated characteristics as mean and median with range for continuous 
variables and as proportions for categorical variables. To search for 
the relationship between pain flare and predictive factors, continu‐
ous parametric and non‐parametric variables were tested with t test 
and	 Mann–Whitney	 test,	 respectively,	 while	 chi‐square	 test	 was	
used for categorical variables. Time‐related events such as PC and 
OS	were	plotted	using	the	Kaplan–Meier	method;	correlation	with	
pretreatment was tested using the log‐rank test. A p‐value	 ≤0.05	
was considered statistically significant. Statistical analysis was per‐
formed with IBM SPSS v.21 statistical software.
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3  | RESULTS
3.1 | Patient‐ and treatment‐related characteristics
A total number of 48 patients with 54 lesions were included in the 
study. The most represented primary tumour was breast adenocar‐
cinoma,	 accounting	 for	 21/54	metastases	 (39%)	 in	 17/48	 patients	
(35%).	Bone	was	 the	only	metastatic	 site	 in	36	patients	out	of	48	
(75%);	 6	 patients	 simultaneously	 received	 SBRT	 to	 two	 bone	me‐
tastases. Bone metastases were predominantly located in the spine 
(n	=	32,	59%),	the	pelvis	(n	=	10,	19%),	the	ribs	(n	=	7,	13%),	the	limbs	
(n	=	4,	7%)	and	in	the	skull	(n	=	1,	2%).	A	pain	level	equal	or	superior	
to	2	in	the	NRS	scale	was	present	in	23	out	of	48	patients,	(48%)	all	
of whom treated for a single lesion. Daily intake of pain medications 
was found in 21 painful patients, consisting of step 1, step 2 and step 
3	drugs	in	7,	3	and	11	patients	respectively.	In	patients	requiring	step	
3	medication,	median	prescribed	dose	was	40	mg	OME	(5–460	mg	
OME). Prescription of prophylactic steroid treatment was found in 
10	patients,	 receiving	a	median	dose	of	8	mg	DXE	 (3–16	mg	DXE).	
Use of steroids was more frequent in patients with concurrent opi‐
oid‐based pain medication (p = 0.02). Patient‐related characteristics 
are reported in Table 1.
Presence	 of	 pain	 complexity	 indicators	was	 evaluated	 according	
to	the	ECS‐CP	tool	 in	23	patients	with	active	pain	before	treatment	
(Table 2). Presence of incident pain was the most prominent ECS‐CP 
feature	(35%),	while	no	cognitive	dysfunction	was	found	in	our	cohort.	
At	least	one	item	was	found	positive	in	13	patients,	while	five	patients	
showed two or more ECS‐CP features. No item or combination of 
items	was	 correlated	with	 administration	 of	 steroids	 or	 opioids,	 ex‐
cept for psychological distress that was correlated with higher steroid 
intake (p = 0.008).
Different dose regimens were used, ranging from 20 to 48 Gy 
in	 1–6	 fractions	 (dose	 per	 fraction	 7–20),	 corresponding	 to	 a	me‐
dian EQD2 prescribed dose of 44.0 Gy10	 (29.8–72.0).	 The	 use	
of a single fraction of 20 Gy was restricted to nine spine me‐
tastases. The most used schedule was 24 Gy in two fractions, 
that	 was	 used	 in	 34	 of	 the	 52	 treatments.	 Treatment‐related	
data	 are	 shown	 in	 Table	 3.	 An	 SBRT	 planning	 case	 is	 provided	 as	
TA B L E  1   Baseline patient‐related characteristics (per patient 
and per treatment site)
Per patient 
(total = 48) %
Per treatment 
site (total = 54) %
Gender
Men 22 46 24 45
Women 26 54 30 55
ECOG performance status
≤1 43 90 48 89
>1 5 10 6 11
Age (median = 65)
≤65	years 31 65 34 63
>65 years 17 35 20 37
Primary tumour
Breast 17 35 21 39
Colorectal 4 8 4 7
Prostate 9 19 10 18
Head and 
neck
1 2 1 2
Non‐small‐
cell lung 
cancer
10 20 10 18
Stomach 3 6 3 6
Thyroid 2 5 2 4
Kidney 2 5 3 6
Prior chemotherapy
Yes 19 40 21 39
No 29 60 33 61
Number of concurrent metastases
1 36 75 36 67
≥2 12 25 18 33
Radiological aspect
Lytic N/A ‐ 28 52
Solid ‐ 17 31
Mixed ‐ 9 17
Site of metastases
Spinal N/A ‐ 32 59
Extraspinal ‐ 22 41
Active	pain	at	baseline	(NRS	≥	2)
No 25 52 31 57
Yes 23 48 23 43
Pain medication
No 25 60 31 57
WHO Step 1 7 13 9 17
WHO Step 2 3 5 3 6
WHO	Step	3 11 22 11 20
Opioids
No opioids 37 77 43 80
(Continues)
Per patient 
(total = 48) %
Per treatment 
site (total = 54) %
≤40	mg	
OME
6 13 6 11
>40 mg 
OME
5 10 5 9
Steroids
No steroids 38 80 42 78
<8	mg	DXE 5 10 7 13
≥8	mg	DXE 5 10 5 9
Note.	 DXE:	 dexamethasone	 equivalent	 (in	 mg);	 OME:	 Oral‐morphine	
equivalent (in mg).
TA B L E  1   (Continued)
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Figure S1. The size of the GTV was correlated at univariate analysis 
with active pain in the treated site (p < 0.001) and consequently with 
prescription of pain medication (p < 0.001) and in particular opioids 
(p = 0.005).
3.2 | Pain flare
Following SBRT, pain flare was reported at the first follow‐up 
visit	in	18	treated	sites,	accounting	for	34%	of	treatments	in	18	
(38%)	patients.	No	other	acute	 side	effects	were	observed	 in	
our	cohort.	Eleven	patients	experienced	pain	flare	as	an	exac‐
erbation	of	pre‐existing	active	pain.	Pain	flare	was	observed	in	
5	of	the	10	patients	(50%)	receiving	prophylactic	steroid	treat‐
ment	 and	 in	 6	 out	 of	 the	 14	 patients	 (43%)	 receiving	 a	weak	
to	 strong	 opioid	medication	 (5/11	 and	 1/3	 for	WHO	 grade	 2	
and	 3	 medication	 respectively).	 Concerning	 tumour	 localisa‐
tion,	 pain	 flare	 occurred	 in	 38%	 of	 spinal	 metastases	 and	 in	
28%	of	extraspinal	metastases	 (12/32	and	6/22	respectively).	
Pain	 flare	 was	 present	 in	 45%	 of	 single‐fraction	 treatments	
(4/9)	 and	 in	 31%	 (14/45)	 of	 multiple	 fraction	 treatments.	 At	
univariate analysis, neither patient‐ nor treatment‐related 
characteristics proved significantly correlated with the onset 
of pain flare. Pain flare regressed spontaneously (n	=	9,	17%)	or	
after a transient increase in pain medication (n	=	9,	17%)	with	
return to baseline intake at the time of the first follow‐up visit 
at 1 month.
3.3 | Pain control
Pain	control	was	obtained	in	14/23	patients	with	baseline	active	pain,	
while no pain progression occurred in any of the previously asympto‐
matic patients. In two patients, surgical rescue due to radiologically 
assessed tumour progression was needed. By plotting pain progres‐
sion	 in	 function	of	 time	with	 the	Kaplan–Meier	method	 (Figure	1,	
left),	PC	was	69%	at	6	months	and	62%	at	1	year,	with	a	median	time	
to	pain	progression	of	29	months	(CI95%	6–52	months).	At	univari‐
ate analysis, only the presence of at least two ECS‐CP features was 
correlated	with	impaired	PC	(median	PC	4	vs.	30	months,	p = 0.012; 
Figure	 1,	 right).	 Median	 follow‐up	 was	 7	months	 (1–71	months).	
Median	overall	survival	was	39	months	 (CI95%	15–64	months),	 re‐
sulting	in	a	6‐month	OS	of	88%	and	a	1‐year	OS	of	75%	(Figure	2).	
Only breast as primary tumour (p = 0.019) and absence of steroid 
pretreatment (p = 0.045) were correlated with longer OS, though 
none of them proved significant at multivariate analysis.
4  | DISCUSSION
Pain flare was a frequent side effect of SBRT and was found in more 
than one third of patients in our series. The occurrence of pain flare 
is a common acute adverse effect in patients treated with CRT pal‐
liative	dose	schedules,	with	reported	incidence	up	to	40%	(Chow	et	
al.,	2005;	Loblaw,	Wu,	Panzarella,	&	T,	Smith	K,	Aslanidis	J,	Warde	P,	
2007) as confirmed by a recent multi‐institutional prospective trial 
N (total = 23) %
Steroids (U 
test)
Opioids (U 
test)
Pain control 
(log‐rank test)
Neuropathic pain
No 17 74 NS NS NS
Yes 6 26
Incident pain
No 15 65 NS NS NS
Yes 8 35
Psychological distress
No 19 83 p = 0.008 NS NS
Yes 4 17
Addictive behaviour
No 22 96 NS NS NS
Yes 1 4
Cognitive dysfunction
No 23 100 – – –
Yes 0 0
ECS‐CP indicators
0 10 44 – – –
≥1 13 56 NS NS NS
≥2 5 22 NS NS p = 0.012
Data in bold represents values that are statistically significant (p < 0.05) at statistical analysis.
TA B L E  2  Pain	complexity	according	to	
ECS‐CP (per patient and per treatment 
site) and correlation with steroid use, 
opioid medication and pain progression in 
patients with active pain at baseline
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(Gomez‐Iturriaga et al., 2015). The cumulative incidence of pain flare 
ranged	 between	 23%–68%	 (Chiang	 et	 al.,	 2013;	 Pan	 et	 al.,	 2014)	
when	patients	were	treated	for	a	spinal	metastases	and	was	10%	for	
extraspinal	sites	(Owen	et	al.,	2014).	According	to	current	literature,	
known predictors of pain flare onset are single‐fraction dose regimen 
(Pan et al., 2014) and lack of steroid pretreatment (Khan et al., 2015). 
Interestingly, no differences in terms of incidence of pain flare were 
found between patient groups, most notably for whom it concerns 
dose schedule and prior administration of steroid premedication. In 
particular, steroid administration before SBRT is based on clinician’s 
judgement in our Institution and not systematically performed: This 
might	 explain	more	 frequent	 use	 of	 steroids	 in	 patients	 receiving	
opioids, whose pain control might appear frailer and influence clini‐
cal decision. Little is known about the physiopathology of pain flare, 
though the most accepted mechanism is radiation‐induced inflam‐
mation with consequent oedema of the periosteum (Svendsen et al., 
2005):	For	this	reason,	the	mean	and	maximum	dose	delivered	to	the	
target lesion and to the planning treatment volume was collected for 
all	patients.	Since	substantial	heterogeneity	existed	among	different	
dose schedules, dose parameters were recalculated in equivalent 
2 Gy doses to allow for comparison. After careful comparison of 
dose/volume parameters and incidence of pain flare, no correlation 
was	 found,	 suggesting	 that	more	complex	mechanisms	 than	 linear	
dose relationship might underlie the development of pain flare: More 
baseline radiobiological studies are probably needed to shed light 
on the dosimetric determinants of this condition and propose dose‐
sparing	strategies.	No	other	toxicities	were	reported	following	SBRT;	
however, longer follow‐up might be needed to confirm the absence 
of chronic complications such as myelopathy and fractures.
We also focused on the subset of patients who presented with 
active pain at baseline evaluation to further characterise their 
conditions and to identify predictors of impaired pain control. As 
expected,	only	the	size	of	the	target	lesion	was	correlated	with	the	
probability to develop pain. In addition to patients and treatment‐
derived variables, we investigated the use and prognostic value of 
the	ECS‐CP,	a	validated	tool	developed	to	study	pain	complexity	
in cancer patients and, consequently, difficulty in achieving ad‐
equate analgesia. Four out of five items that compose the tool 
were correctly identified in our cohort; only cognitive impairment 
was not found in any patients, probably due to scarce compliance 
of those patients to the stringent requirements of SBRT that re‐
sulted in selection of patients with preserved cognitive function. 
Conversely, addiction to alcohol and cannabis was found in one 
case. Incident pain (n = 8) and neuropathic component (n = 6) 
were	the	most	frequently	 identified	complexity	indicators,	while	
psychological distress linked to pain‐related aspects of the dis‐
ease was assessed in four patients. Interestingly, the presence of 
≥2	ECS‐CP	complexity	 indicators	was	correlated	 to	shorter	pain	
control, resulting in a time to pain progression of 4 months vs. 
30	months.	There	is	a	lack	of	data	concerning	the	applicability	of	
the ECS‐CP tool in the pain outcome after radiotherapy to painful 
metastases. However, if further assessment is warranted in larger 
prospective cohorts, the ECS‐CP may prove useful to stratify pa‐
tients	in	function	of	the	expected	benefit	from	radiotherapy	and	
to identify other critical areas of intervention (such as pharma‐
cological/neurosurgical management of neuropathic pain, early 
diagnosis and counselling for psychological distress, and manage‐
ment	of	addictive	behaviours)	in	order	to	overcome	pain	complex‐
ity and obtain adequate analgesia.
Pain	 control	 at	 1	year	was	maintained	 in	62%	of	 patients	with	
active pain prior to SBRT. Data from literature show pain control 
in	27%–100%	of	patients	at	6	months	(Chang,	Youn,	Park,	&	Rhee,	
2009;	Gibbs	&	Radiosurgery,	2003;	Wang	et	al.,	2012)	and	54%–85%	
(Nguyen et al., 2010; Sheehan et al., 2009) at 1 year. However, defi‐
nition of pain control was inconsistent among different studies or 
was not clearly distinguished from pain response: For this reason, 
we have chosen the more stringent definition used by Chow et al. 
(2005). Moreover, in the majority of cases, pain control evaluation 
was carried out in the whole treated population and not only in the 
subgroup with baseline pain. Future prospective studies should 
agree on common definition for this endpoint and selection of the 
target population, in order to allow for interstudy comparison. It 
TA B L E  3   Treatment‐related characteristics (per treatment site)
N (total=54) %
Dose Fractionation
Single fraction 9 17
Multiple fractions 45 83
GTV in cm3
≤33 39 72
>33 15 28
PTV in cm3
≤64 34 63
>64 20 37
Total dose prescribed in Gy10
≤44 36 67
>44 18 33
Maximum	dose	to	PTV	in	Gy10
≤62 27 50
>62 27 50
Mean dose to PTV in Gy10
≤48 28 52
>48 26 48
Total dose prescribed in Gy3
≤72 36 67
>72 18 33
Maximum	dose	to	PTV	in	Gy3
≤107 27 50
>107 27 50
Mean dose to PTV in Gy3
≤82 28 52
>82 26 48
Note. Median values were used as cut‐off for statistical analysis.
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is noteworthy that, in our cohort, median survival after SBRT was 
39	months,	 with	 only	 12%	 of	 patients	 deceasing	 within	 6	months	
of	the	treatment.	Due	to	expected	long	survival,	it	is	mandatory	to	
obtain durable pain control in metastatic patients and to consider 
multidisciplinary management to achieve this goal, even in case of 
treatment	failure	(Mercadante	&	Fulfaro,	2007):For	example,	surgi‐
cal rescue was possible in two patients with painful bone progres‐
sion after SBRT.
There are several limitations in our study. In first instance, its 
retrospective design with subsequent risk of bias due to data loss, 
lack of control on confounders and possible under‐report of addic‐
tive behaviours. Secondarily the small sample size did not allow for 
further subset analysis. This could be particularly useful in patients 
with	complex	pain	profile	who	might	deserve	further	characterisa‐
tion according to the predominant ECS‐CP feature in order to better 
assess areas of therapeutic intervention. Finally, due to technical 
complexity	of	SBRT	compared	to	palliative	RT,	a	selection	bias	may	
have occurred resulting in the indication to SBRT restricted only to 
compliant, cognitively non‐impaired patients. To investigate pain 
treatment outcome after SBRT and the possible predictive role of 
tools such as ECS‐CP, future studies need to be conducted prospec‐
tively, enrolling larger samples of patients for an adequate follow‐up 
time with clear identification of predictive factors and combined use 
of other pain management modalities.
5  | CONCLUSIONS
In patients affected by bone metastases treated by SBRT, pain flare 
was	observed	in	38%	of	cases	irrespectively	of	steroid	premedica‐
tion and dose regimen. In patient with active pain at baseline, pain 
control	was	obtained	 in	62%	of	patients	at	1	year.	Presence	of	≥2	
complexity	indicators	at	the	ECS‐CP	assessment	was	correlated	with	
impaired pain control and may deserve future investigation in pro‐
spective studies.
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